Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,417 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma
Interventions: MB-CART19.1 Cellular Therapy; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Irritable Mood
Interventions: Functional MRI (fMRI), Oxytocin Intranasal Spray 8 International Unit (8IU), Oxytocin intranasal spray 24 International Unit (24IU), Oxytocin intranasal spray 48 International Unit (48IU), Oxytocin intranasal spray 80 International Unit (80IU), Placebo; Procedure · Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 14 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pruritus, Pregnancy Related
Interventions: Promethazine, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Discogenic Pain
Interventions: High yield pure PRP, Placebo, ProPlaz PPC; Device · Other
Lead sponsor: Neurological Associates of West Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Campbell, California • Santa Monica, California • Peachtree City, Georgia + 2 more

Conditions: Asthma
Interventions: ELLIPTA DPI, GSK MDI, AZ MDI; Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more

Conditions: Blood Clots, Vascular Disease, Embolism Thrombosis, Cardiovascular Diseases, Lung Diseases
Interventions: Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter; Device
Lead sponsor: Liquet Medical Inc.; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Osteoarthritis
Interventions: Bone Marrow Derived MSCs, Adipose-derived MSCs, Umbilical Cord Tissue (UCT) MSCs, Corticosteroid injection; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Gulf Breeze, Florida • Atlanta, Georgia • Durham, North Carolina + 2 more

Conditions: Postoperative Nausea and Vomiting
Interventions: Intravenous fluid, D5LR or lactated ringers; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Spinal Cord Injury
Interventions: CSFD and elevation of MAP, Maintenance of MAP; Procedure
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona

Conditions: Dehydration
Interventions: hylenex-facilitated subcutaneous Lactated Ringer's infusion; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Lincoln, Nebraska • Neptune City, New Jersey

Conditions: Chronic Wounds
Interventions: Swabs; Other
Lead sponsor: Systagenix Wound Management; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Multiple Sclerosis
Interventions: single-use autoinjector with a prefilled liquid Avonex syringe, Avonex prefilled syringe via manual IM injection, BG9418 (interferon beta-1a); Device · Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 16
States / cities: Gilbert, Arizona • Phoenix, Arizona • Maitland, Florida + 13 more

Conditions: Angelman Syndrome, Chromosome 15q Duplication (dup15q) Syndrome
Interventions: Lumbar Puncture, Blood Collection; Procedure
Lead sponsor: Biogen; Industry
Eligibility: Up to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Heart Failure, Decompensated Heart Failure, Hospital Length of Stay
Interventions: Point-of-Care Ultrasound (POCUS); Device
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Autism Spectrum Disorder
Interventions: baclofen, intrathecal; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 10 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site
Interventions: FoundationOne CDx and FoundationOne Liquid CDx; Diagnostic Test
Lead sponsor: TargetCancer Foundation; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Immune Globulin Subcutaneous (Human); Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Pancreatitis
Interventions: Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Rochester, Minnesota • Columbus, Ohio

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 24 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 4 more

Conditions: Kidney Transplant, Fluid Management
Interventions: Phenotype-Guided Vasoactive Management; Drug
Lead sponsor: Jennifer Cutler; Other
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pseudotumor Cerebri, Idiopathic Intracranial Hypertension (IIH)
Interventions: Dural Venous Sinus Stenting, Cerebrospinal Fluid Shunting; Device
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Seattle, Washington

Conditions: Ascites, Cirrhosis
Interventions: Residency Program Teaching, Lecture, Pocket Card Reference, Pager; Behavioral · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: Not listed
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Skin Reactions Secondary to Radiation Therapy
Interventions: Dakin's solution, radiation therapy, questionnaire administration, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Glucose Transporter Type 1 Deficiency Syndrome
Interventions: UX007; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Year and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • New York, New York + 2 more

Search by objective public record fields.

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Dose Response Relationship of Oxytocin on Irritability in Youths

Treatment of Pruritus With Intramuscular Promethazine

Safety and Efficacy of PRP for Treatment of Disc Pain

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter

Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)

A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting

Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase

Swab Sample Collection for the Detection of Bacterial Proteases

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

Angelman Syndrome (AS) Biomarker Study

Use of Point-of-Care Ultrasound (POCUS) to Reduce Hospital Length of Stay in Patients With Heart Failure ( POCUSHF )

Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Trial of Indomethacin in Chronic Pancreatitis

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phenotype Guided Vasoactive Medication During Kidney Transplantation

Operative Procedures Vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial

Improving Performance of Paracentesis in Medical Residency Training

Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy

Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)